Literature DB >> 22107336

ACR appropriateness criteria(®) ductal carcinoma in situ.

Meena S Moran1, Harrison X Bai, Eleanor E R Harris, Douglas W Arthur, Lisa Bailey, Jennifer R Bellon, Lisa Carey, Sharad Goyal, Michele Y Halyard, Kathleen C Horst, Shannon M MacDonald, Bruce G Haffty.   

Abstract

Ductal carcinoma in situ (DCIS) describes a wide spectrum of non-invasive tumors which carry a significant risk of invasive relapse, thus prevention of local recurrence is vital. For appropriate patients with limited disease, management with breast conserving surgery (BCS) followed by whole-breast radiation (RT) is supported by multiple Phase III studies, but mastectomy may be appropriate in selected patients. Omission of RT may also be reasonable in some patients, though which criteria are to be utilized remain unclear, and the existing data are contradictory with limited follow-up. Various RT techniques such as boost to the tumor bed, partial breast radiation or hypofractionated, whole-breast RT are increasingly utilized but the data to support their use specifically in DCIS is limited. Tamoxifen also increases local control for ER + DCIS, adding to the complexity of the local treatment management. This article reviews the existing scientific evidence, the controversies surrounding local management, and clinical guidelines for DCIS based on the group consensus by the ACR Breast Expert Panel. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
© 2011 American College of Radiology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22107336     DOI: 10.1111/j.1524-4741.2011.01197.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  9 in total

Review 1.  Management of Ductal Carcinoma In Situ (DCIS) of the Breast: Present Approaches and Future Directions.

Authors:  Lawrence J Solin
Journal:  Curr Oncol Rep       Date:  2019-03-05       Impact factor: 5.075

2.  International variation in management of screen-detected ductal carcinoma in situ of the breast.

Authors:  Antonio Ponti; Elsebeth Lynge; Ted James; Ondřej Májek; My von Euler-Chelpin; Ahti Anttila; Patricia Fitzpatrick; Maria Piera Mano; Masaaki Kawai; Astrid Scharpantgen; Jacques Fracheboud; Solveig Hofvind; Carmen Vidal; Nieves Ascunce; Dolores Salas; Jean-Luc Bulliard; Nereo Segnan; Karla Kerlikowske; Stephen Taplin
Journal:  Eur J Cancer       Date:  2014-08-19       Impact factor: 9.162

Review 3.  De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer.

Authors:  E Shelley Hwang; Lawrence Solin
Journal:  J Clin Oncol       Date:  2020-05-22       Impact factor: 44.544

4.  Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma.

Authors:  Neda Rezaee; Carlotta Barbon; Ahmed Zaki; Jin He; Bulent Salman; Ralph H Hruban; John L Cameron; Joseph M Herman; Nita Ahuja; Anne Marie Lennon; Matthew J Weiss; Laura D Wood; Christopher L Wolfgang
Journal:  HPB (Oxford)       Date:  2015-12-10       Impact factor: 3.647

5.  Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.

Authors:  Lawrence J Solin; Robert Gray; Lorie L Hughes; William C Wood; Mary Ann Lowen; Sunil S Badve; Frederick L Baehner; James N Ingle; Edith A Perez; Abram Recht; Joseph A Sparano; Nancy E Davidson
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

Review 6.  Ductal Carcinoma In Situ of the Breast: Evaluating the Role of Radiation Therapy in the Management and Attempts to Identify Low-risk Patients.

Authors:  Chirag Shah; Frank A Vicini; Sameer Berry; Thomas B Julian; John Ben Wilkinson; Simona F Shaitelman; Atif Khan; Steven E Finkelstein; Neal Goldstein
Journal:  Am J Clin Oncol       Date:  2015-10       Impact factor: 2.339

7.  Preoperatively diagnosed ductal cancers in situ of the breast presenting as even small masses are of high risk for the invasive cancer foci in postoperative specimen.

Authors:  Bartlomiej Szynglarewicz; Piotr Kasprzak; Agnieszka Halon; Rafal Matkowski
Journal:  World J Surg Oncol       Date:  2015-07-16       Impact factor: 2.754

8.  Effect of Referral Patterns and Treatment Type on Oncologic Outcomes for Women with Ductal Carcinoma In Situ.

Authors:  Elaine S Wai; Mary Lesperance; Linghong Lu; Cheryl S Alexander; Pauline T Truong
Journal:  Cureus       Date:  2017-03-31

9.  A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.

Authors:  Lawrence J Solin; Robert Gray; Frederick L Baehner; Steven M Butler; Lorie L Hughes; Carl Yoshizawa; Diana B Cherbavaz; Steven Shak; David L Page; George W Sledge; Nancy E Davidson; James N Ingle; Edith A Perez; William C Wood; Joseph A Sparano; Sunil Badve
Journal:  J Natl Cancer Inst       Date:  2013-05-02       Impact factor: 13.506

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.